Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29156
Title: Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years
Authors: Vermersch, P.
Baker, M.
Bass, A. D.
Berkovich, R.
Comi, G.
Eichau, S.
Graves, D.
Hunter, S. F.
Ionete, C.
Limmroth, V.
Meuth, S. G.
Naismith, R. T.
Sharrack, B.
Subei, A.
Daizadeh, N.
Choudhry, Z.
VAN WIJMEERSCH, Bart 
Issue Date: 2019
Publisher: WILEY
Source: EUROPEAN JOURNAL OF NEUROLOGY, 26(SI), p. 866-867
Notes: [Vermersch, P.] Univ Lille, Lille, France. [Baker, M.] Collier Neurol Specialists, Naples, FL USA. [Bass, A. D.] Neurol Ctr San Antonio, San Antonio, TX USA. [Berkovich, R.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy. [Eichau, S.] Hosp Univ Virgen Macarena, Seville, Spain. [Graves, D.] Atrium Hlth, Neurosci Inst Neurol, Charlotte, NC USA. [Hunter, S. F.] Adv Neurosci Inst, Franklin, TN USA. [Ionete, C.] Univ Massachusetts, Mem Med Ctr, Worcester, MA 01605 USA. [Limmroth, V.] Klin Neurol & Palliat Med, Cologne, Germany. [Meuth, S. G.] Univ Munster, Munster, Germany. [Naismith, R. T.] Washington Univ, Sch Med, St Louis, MO USA. [Sharrack, B.] Univ Sheffield, Sheffield, S Yorkshire, England. [Sharrack, B.] Sheffield Teaching Hosp, Sheffield, S Yorkshire, England. [Subei, A.] Mem Healthcare Syst, Hollywood, FL USA. [Daizadeh, N.; Choudhry, Z.] Sanofi, Cambridge, MA USA. [Van Wijmeersch, B.] Hasselt Univ, BIOMED, Rehabil & MS Ctr Overpelt, Hasselt, Belgium.
Document URI: http://hdl.handle.net/1942/29156
ISSN: 1351-5101
e-ISSN: 1468-1331
ISI #: 000474481004026
Category: M
Type: Journal Contribution
Appears in Collections:Research publications

Show full item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.